[Study of the practice of prescribing phenosanic acid in epilepsy accompanied by asthenic disorders].

Autor:	Lebedeva AV; Federal Center of Brain and Neurotechnologies, Moscow, Russia.; Pirogov Russian National Research Medical University, Moscow, Russia.; Research Institute of Health Care Organization and Medical Management, Moscow, Russia., Burd SG; Federal Center of Brain and Neurotechnologies, Moscow, Russia.; Pirogov Russian National Research Medical University, Moscow, Russia., Rubleva YV; Federal Center of Brain and Neurotechnologies, Moscow, Russia., Pantina NV; Federal Center of Brain and Neurotechnologies, Moscow, Russia., Yurchenko AV; Federal Center of Brain and Neurotechnologies, Moscow, Russia., Bogomazova MA; Federal Center of Brain and Neurotechnologies, Moscow, Russia., Kovaleva II; Federal Center of Brain and Neurotechnologies, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2024; Vol. 124 (7), pp. 89-97.
DOI:	10.17116/jnevro202412407189
Abstrakt:	Objective: To evaluate the experience of prescribing phenosanic acid in the practice of a neurologist/epileptologist when prescribing the second, third anticonvulsant drug (AED) as part of combination therapy for patients with manifestations of fatigue due to epilepsy. Material and Methods: 501 patients with focal epilepsy accompanied by asthenic disorders were included in the observational program. The observation program protocol included 5 visits, including visit 1, at which screening and inclusion in the OP took place. The observation period was 10 months. At baseline and at the end of the 10-month follow-up, the patients' condition was assessed according to the following indicators: frequency and transformation of attacks with focal onset, severity of fatigue (self-assessment scale MFI-20); quality of life (questionnaire QoLiE-10-P); frequency of attacks with focal onset. The safety of phenosanic acid (Dibufelon) was also assessed. Results: In 10 months after the inclusion of Dibufelon as the 2nd, 3rd AED in the treatment regimen, a statistically significant ( p <0.01) decrease in the frequency of seizures was observed: in general - in 88% of patients; by 50% or more - in 76% of patients; transition from the group with a large number of seizures to the group with a smaller number of seizures - 74% of patients. Also when taking phenosanic acid, a positive dynamics of seizure type was noted: a reliable decrease in the proportion of patients with seizures with secondary generalization from 70% to 56%; a decrease in the number of focal seizures with impaired consciousness from 65% to 53%. In addition, there was a 38% decrease in the severity of fatigue on the MFI-20 scale (the greatest decrease on the «Mental fatigue» scale), improvement in the quality of life - a 2.7-fold increase in the mean values of the QOLIE-10 questionnaire. Conclusion: The addition of phenosanic acid to antiepileptic therapy as a second or third AED allows for better control of seizures, leading to a decrease the frequency and severity of attacks and the severity of fatigue both, and an increase of the quality of life of patients with epilepsy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu